ARS Pharmaceuticals Financials - Benzinga

ARS Pharmaceuticals Inc

SPRYNASDAQ

Trade with Public

Trade with Public

$6.41

0.111.75%

At close: Aug 19, 5:00 PM EST

Earnings: Q2 2026 Earnings were released on Thu Aug 13th, after the market close

Conference Call: The most recent conference call started at 4:30 PM, 6 days ago

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

ARS Pharmaceuticals Financials

ARS Pharmaceuticals (SPRY) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ARS Pharmaceuticals Q2 EPS $(0.63) Misses $(0.48) Estimate, Sales $33.658M Beat $31.321M Estimate

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.48) by 31.25 percent. This is a 36.96 percent decrease over losses of $(0.46) per share

Benzinga Newsdesk

ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage

SPRY stock drops after ARS says no new neffy coverage decisions in July formulary cycle.

Tanya Rawat

PRO
ARS Pharma Lowers 2026 Cash Operating Expense Guidance To $248M And Reaffirms Path To Cash-Flow Breakeven In 2027

No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusionTotal 2026 cash-based

Benzinga Newsdesk

Earnings Scheduled For May 15, 2026

Benzinga Insights

PRO
ARS Pharmaceuticals Q1 EPS $(0.61) Misses $(0.52) Estimate, Sales $22.681M Beat $22.230M Estimate

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 74.29 percent decrease over losses of $(0.35) per share

Benzinga Newsdesk

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share.

Avi Kapoor